**Specifications Table**TableSubject areaBiologyMore specific subject areaDyslipidemia and cardiovascular riskType of dataTablesHow data was acquiredWorldwide surveyData formatAnalyzedExperimental factorsObservational registryExperimental featuresComparison of LDL-C target achievement and distance to target in patients on chronic statin therapy at differing risk of cardiovascular events.Data source locationInstitut für Herzinfarktforschung, Ludwigshafen, GermanyData accessibilityData are included in this article

**Value of the data**•These data are gathered from a large, worldwide registry and insights are therefore applicable to physicians globally.•As data are stratified by individual country, target attainment within different national healthcare systems can be compared and potential improvements made based on the experience of more successful countries.•Data can be used as a basis from which to launch further studies investigating optimal treatment regimes for patients at risk of cardiovascular events, both globally and within individual countries.

1. Data {#s0005}
=======

[Table 1](#t0005){ref-type="table"} displays the proportion of patients attaining risk based target LDL-C values in a global cohort, overall and divided by country and region of the world. [Table 2](#t0010){ref-type="table"} displays the median distance to risk based treatment targets in a global cohort, overall and divided by country and region of the world.

2. Experimental design, materials and methods {#s0010}
=============================================

The methodology for DYSIS (a cross-sectional, observational, multicenter registry) has been described elsewhere [@bib1]. Briefly, statin-treated (mono/combination therapy) outpatients were consecutively enrolled at multiple centers located in 30 different countries worldwide. The study was approved by the relevant ethics committees and carried out in agreement with local laws.

Inclusion criteria were as follows: 1) provision of written informed consent, 2) availability of a fasting blood lipid profile taken within 6--12 months of study entry, at which time the participant had been on statin therapy for a minimum of 3 months 3) aged ≥45 years and on statin therapy at time of inclusion 4) not participating in a clinical trial.

The 2011 ESC/EAS guidelines on treatment of dyslipidemia were used for stratification of patients into risk categories [@bib2]. Patients considered at "very high risk" of cardiovascular events were those diagnosed with CHD, diabetes, chronic kidney disease, and/or peripheral artery disease, whereas those with markedly elevated single risk factors such as total cholesterol \>310 mg/dl or severe hypertension (SBP≥180 and/or DBP≥110 mmHg) were determined to be "high-risk". All other patients were determined to be "not high-risk". LDL-C targets of 70 mg/dl, 100 mg/dl, and 115 mg/dl were assigned to very high-, high- and non-high-risk patients, respectively, in accordance with 2011 ESC/EAS guidelines.

Serum lipid levels were obtained from the most recent blood test for each patient, and data on lipid-lowering agents (statin type, dose, and other concomitant lipid-modifying therapies) that were being taken by the patient at that time were documented. Simvastatin was used as a reference to calculate the relative potency of other statins for comparison [@bib3]. A central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany was used to collect and store the data.

The SAS^©^ statistical package, Version 9.3 (SAS Institute, Cary, North Carolina, USA) was used for data analysis purposes. Data were processed and presented as percentages (*n*/*N*) or medians (IQR), all of which were based one the number of patients with data for a particular case available. Categorical variables were compared by Chi-squared tests and continuous variables by Mann--Whitney--Wilcoxon (two-tailed) or Kruskal--Wallis (three-tailed) tests. In terms of distance from target, a smaller value was considered to represent greater target achievement, while a larger value represented poorer target achievement. *P*-values ≤0.05 were considered significant.
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=============================================
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###### 

Proportions of patients attaining their target LDL-C values.

Table 1

  Country (*n*)                Total                  Very high-risk[a](#tbl1fna){ref-type="table-fn"}   High-risk[a](#tbl1fna){ref-type="table-fn"}   Non-high-risk[a](#tbl1fna){ref-type="table-fn"}   *P*-value
  ---------------------------- ---------------------- -------------------------------------------------- --------------------------------------------- ------------------------------------------------- -----------
  **Europe/Canada/Israel**                                                                                                                                                                               
  Austria (*n*=881)            15.9 (123/772)         12.9 (85/657)                                      20.7 (6/29)                                   37.2 (32/86)                                      \<0.0001
  Baltics (*n*=1797)           15.9 (282/1779)        10.9 (151/1386)                                    20.5 (24/117)                                 38.8 (107/276)                                    \<0.0001
  Belgium (*n*=909)            35.7 (310/868)         21.6 (116/536)                                     40.5 (34/84)                                  64.5 (160/248)                                    \<0.0001
  Canada (*n*=2436)            45.6 (1098/2410)       40.7 (787/1933)                                    50.3 (79/157)                                 72.5 (232/320)                                    \<0.0001
  Denmark (*n*=933)            37.7 (338/897)         30.2 (196/650)                                     45.4 (49/108)                                 66.9 (93/139)                                     \<0.0001
  France (*n*=4192)            20.6 (835/4061)        14.4 (385/2677)                                    16.6 (50/302)                                 37.0 (400/1082)                                   \<0.0001
  Germany (*n*=4216)           14.3 (555/3879)        11.2 (371/3300)                                    18.9 (44/233)                                 40.5 (140/346)                                    \<0.0001
  Greece (*n*=755)             17.8 (132/741)         9.2 (42/456)                                       19.1 (9/47)                                   34.0 (81/238)                                     \<0.0001
  Ireland (*n*=900)            43.5 (376/865)         35.9 (222/618)                                     58.6 (51/87)                                  64.4 (103/160)                                    \<0.0001
  Israel (*n*=100)             29.1 (223/766)         20.3 (121/597)                                     49.0 (24/49)                                  65.0 (78/120)                                     \<0.0001
  Italy (*n*=766)              30.7 (206/671)         22.7 (95/419)                                      29.4 (15/51)                                  47.8 (96/201)                                     \<0.0001
  The Netherlands (*n*=1199)   30.8 (354/1151)        27.4 (279/1019)                                    34.1 (15/44)                                  68.2 (60/88)                                      \<0.0001
  Norway (*n*=957)             29.2 (247/847)         18.5 (112/607)                                     46.2 (48/104)                                 64.0 (87/136)                                     \<0.0001
  Portugal (*n*=910)           20.4 (144/706)         11.1 (46/415)                                      25.0 (13/52)                                  35.6 (85/239)                                     \<0.0001
  Russia (*n*=1585)            17.0 (189/1114)        12.2 (118/967)                                     30.3 (10/33)                                  53.5 (61/114)                                     \<0.0001
  Slovakia (*n*=926)           24.5 (226/923)         16.5 (121/733)                                     37.3 (19/51)                                  61.9 (86/139)                                     \<0.0001
  Slovenia (*n*=766)           23.6 (178/755)         19.1 (122/640)                                     25.6 (10/39)                                  60.5 (46/76)                                      \<0.0001
  Spain (*n*=3664)             16.7 (580/3463)        10.1 (221/2186)                                    17.9 (48/268)                                 30.8 (311/1009)                                   \<0.0001
  Sweden (*n*=958)             27.6 (223/807)         21.4 (141/660)                                     45.3 (34/75)                                  66.7 (48/72)                                      \<0.0001
  UK (*n*=1315)                40.9 (426/1041)        38.3 (353/922)                                     50.0 (13/26)                                  64.5 (60/93)                                      \<0.0001
                                                                                                                                                                                                         
  **Middle East/Africa**                                                                                                                                                                                 
  Egypt (*n*=1457)             18.8 (260/1384)        13.2 (157/1188)                                    28.2 (11/39)                                  58.6 (92/157)                                     \<0.0001
  Lebanon/Jordan (*n*=603)     41.6 (221/531)         33.0 (120/364)                                     37.1 (13/35)                                  66.7 (88/132)                                     \<0.0001
  UAE and Kuwait (*n*=299)     49.5 (135/273)         44.9 (105/234)                                     40.0 (2/5)                                    82.4 (28/34)                                      \<0.001
  Saudi Arabia (*n*=1263)      32.5 (388/1194)        26.4 (276/1045)                                    52.9 (9/17)                                   78.0 (103/132)                                    \<0.0001
  South Africa (*n*=1029)      48.6 (478/984)         39.9 (288/722)                                     66.7 (60/90)                                  75.6 (130/172)                                    \<0.0001
                                                                                                                                                                                                         
  **Asia**                                                                                                                                                                                               
  China (*n*=22,369)           31.4 (7006/22,345)     23.9 (4067/17,022)                                 46.4 (687/1481)                               58.6 (2252/3842)                                  \<0.0001
  **Total** (*n*=57,885)       28.1 (15,533/55,227)   21.7 (9097/41,953)                                 38.0 (1377/3623)                              52.4 (5059/9651)                                  \<0.0001

Corresponding LDL-C targets for very high-, high- and non-high-risk patients were \<70 mg/dl, \<100 mg/dl and 115 mg/dl, respectively.

###### 

Median distance to treatment targets.

Table 2

  Country (*n*)                Total[a](#tbl2fna){ref-type="table-fn"} mg/dl (IQR)   Very high-risk[b](#tbl2fnb){ref-type="table-fn"} mg/dl (IQR)   High-risk[b](#tbl2fnb){ref-type="table-fn"} mg/dl (IQR)   Non-high-risk[b](#tbl2fnb){ref-type="table-fn"} mg/dl (IQR)   *P*-value
  ---------------------------- ----------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------- -----------
  **Europe/Canada/Israel**                                                                                                                                                                                                                                                  
  Austria (*n*=881)            33.0 (18.0, 58.0)                                     33.0 (19.0, 58.0)                                              31.0 (9.0, 67.0)                                          25.5 (9.0, 56.0)                                              0.06
  Baltics (*n*=1797)           42.1 (20.5, 71.9)                                     42.5 (21.6, 73.9)                                              33.0 (12.9, 69.4)                                         38.1 (15.3, 60.9)                                             \<0.05
  Belgium (*n=*909)            24.3 (11.0, 44.0)                                     27.5 (14.0, 47.0)                                              14.5 (7.0, 30.0)                                          14.0 (5.0, 33.5)                                              \<0.0001
  Canada (*n*=2436)            18.8 (8.5, 34.4)                                      18.9 (8.5, 34.4)                                               17.7 (6.3, 33.4)                                          17.1 (8.4, 31.9)                                              0.79
  Denmark (*n*=933)            24.2 (11.2, 42.1)                                     26.7 (13.9, 42.1)                                              22.6 (8.3, 46.9)                                          16.5 (4.9, 28.9)                                              \<0.01
  France (*n*=4192)            35.0 (18.0, 58.0)                                     38.0 (19.0, 61.0)                                              36.5 (17.0, 61.0)                                         28.0 (15.0, 48.0)                                             \<0.0001
  Germany (*n*=4216)           38.0 (20.0, 61.0)                                     39.0 (22.0, 62.0)                                              31.0 (14.8, 54.0)                                         28.1 (15.0, 45.9)                                             \<0.0001
  Greece (*n*=755)             37.0 (20.0, 60.0)                                     40.0 (22.0, 65.0)                                              35.0 (21.0, 50.0)                                         28.0 (15.0, 50.0)                                             \<0.01
  Ireland (*n*=900)            25.5 (11.2, 46.0)                                     26.7 (12.6, 46.0)                                              26.8 (14.7, 44.4)                                         19.6 (8.7, 38.1)                                              0.13
  Israel (*n*=100)             21.0 (9.0, 38.0)                                      21.3 (9.0, 39.0)                                               23.0 (12.0, 29.0)                                         13.0 (7.0, 29.0)                                              0.13
  Italy (*n*=766)              29.0 (13.0, 53.0)                                     32.0 (17.0, 55.5)                                              22.5 (7.0, 61.5)                                          22.0 (9.0, 37.0)                                              \<0.001
  The Netherlands (*n*=1199)   26.7 (11.6, 42.5)                                     26.7 (11.2, 42.1)                                              27.6 (13.7, 46.9)                                         31.8 (10.1, 39.7)                                             0.83
  Norway (*n*=957)             30.5 (15.1, 49.9)                                     30.5 (18.9, 51.0)                                              16.0 (4.4, 31.7)                                          16.5 (4.9, 47.4)                                              \<0.0001
  Portugal (*n*=910)           39.5 (21.0, 60.0)                                     42.0 (23.0, 65.0)                                              35.0 (23.0, 56.0)                                         33.0 (16.0, 54.0)                                             \<0.01
  Russia (*n*=1585)            38.3 (18.9, 63.0)                                     38.3 (18.9, 65.0)                                              26.8 (8.3, 66.7)                                          28.5 (10.3, 42.4)                                             \<0.01
  Slovakia (*n*=926)           37.1 (18.2, 65.3)                                     38.7 (19.3, 68.4)                                              35.3 (16.4, 66.7)                                         18.8 (8.0, 31.9)                                              \<0.0001
  Slovenia (*n*=766)           38.3 (18.9, 69.2)                                     39.2 (18.9, 69.2)                                              23.7 (12.1, 54.7)                                         30.8 (16.5, 47.4)                                             0.05
  Spain (*n*=3664)             39.0 (20.0, 64.0)                                     42.0 (23.0, 69.0)                                              39.5 (19.5, 61.0)                                         32.0 (14.0, 54.0)                                             \<0.0001
  Sweden (*n*=958)             26.7 (15.1, 46.0)                                     26.7 (15.1, 46.0)                                              27.6 (12.1, 46.9)                                         12.6 (8.7, 22.3)                                              \<0.01
  UK (*n*=1315)                19.3 (11.2, 36.3)                                     19.3 (11.2, 35.6)                                              28.4 (4.4, 40.8)                                          24.2 (4.9, 51.3)                                              0.98
                                                                                                                                                                                                                                                                            
  **Middle East/Africa**                                                                                                                                                                                                                                                    
  Egypt (*n*=1457)             40.0 (20.0, 71.0)                                     42.0 (20.0, 75.0)                                              38.5 (22.0, 65.0)                                         29.0 (13.0, 47.0)                                             \<0.01
  Lebanon/Jordan (*n*=603)     30.0 (13.0, 58.0)                                     30.0 (13.0, 59.5)                                              25.5 (11.0, 37.0)                                         27.0 (13.5, 57.5)                                             0.37
  UAE and Kuwait (*n*=299)     25.0 (9.0, 41.0)                                      25.0 (9.0, 42.0)                                               23.0 (2.0, 88.0)                                          11.5 (5.0, 24.0)                                              0.42
  Saudi Arabia (*n*=1263)      34.0 (15.1, 56.0)                                     37.0 (17.0, 57.6)                                              13.5 (7.1, 24.0)                                          11.0 (6.0, 22.0)                                              \<0.0001
  South Africa (*n*=1029)      30.3 (14.3, 52.6)                                     30.5 (14.3, 53.7)                                              25.1 (13.7, 43.1)                                         34.7 (13.0, 53.2)                                             0.54
                                                                                                                                                                                                                                                                            
  **Asia**                                                                                                                                                                                                                                                                  
  China (*n*=22,369)           33.1 (15.5, 56.8)                                     34.8 (16.6, 59.5)                                              24.9 (11.8, 45.8)                                         24.2 (10.7, 43.5)                                             \<0.0001
  Total (*n*=57,885)           33.0 (15.8, 57.0)                                     34.4 (17.0, 59.0)                                              28.0 (12.1, 51.2)                                         25.8 (12.0, 47.0)                                             \<0.0001

Total refers to the distance from individual treatment targets, irrespective of group.

Corresponding LDL-C targets for very high-, high- and non-high-risk patients were \<70 mg/dl, \<100 mg/dl and 115 mg/dl, respectively (given distance from target is relative to these values).
